Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

被引：0
|
作者：
Kim, G. P.
Oberg, A. L.
Foster, N. R.
Jaslowski, A.
Flynn, P. J.
Campbell, D.
Hedrick, E.
Gray, L.
Grothey, A.
Alberts, S.
机构：
[1] North Cent Canc Treatment Grp, Rochester, MN USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Genentech BioOncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC).
    Chiang, Nai-Jung
    Tsai, Kelvin K.
    Chen, Jen-Shi
    Yang, Shih-Hung
    Hsu, Chiun
    Shan, Yan-Shen
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:: a randomized phase II trial
    Scheithauer, W
    Schüll, B
    Ulrich-Pur, H
    Schmid, K
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Schneeweiss, B
    Lang, F
    Kornek, GV
    ANNALS OF ONCOLOGY, 2003, 14 (01) : 97 - 104
  • [23] Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F., Jr.
    Zon, R.
    Mowat, R. B.
    McCullough, A.
    Meyers, J. P.
    Alberts, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F.
    Zon, R.
    Mowat, R. B.
    Wiesenfeld, M.
    McCullough, A. E.
    Alberts, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Zhu, AX
    Blaszkowsky, LS
    Ryan, DP
    Clark, JW
    Muzikansky, A
    Horgan, K
    Sheehan, S
    Hale, KE
    Enzinger, PC
    Bhargava, P
    Stuart, K
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1898 - 1903
  • [26] A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer.
    Xiong, HQ
    Hess, KR
    Kayaleh, OR
    Goodwin, JW
    Banerjee, T
    Sinclair, SS
    Fisch, MJ
    Wolff, RA
    Abbruzzese, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 351S - 351S
  • [27] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Roberto Petrioli
    Giandomenico Roviello
    Anna Ida Fiaschi
    Letizia Laera
    Daniele Marrelli
    Franco Roviello
    Edoardo Francini
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 683 - 690
  • [28] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Petrioli, Roberto
    Roviello, Giandomenico
    Fiaschi, Anna Ida
    Laera, Letizia
    Marrelli, Daniele
    Roviello, Franco
    Francini, Edoardo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 683 - 690
  • [29] A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Ko, Andrew H.
    Youssoufian, Hagop
    Gurtler, Jayne
    Dicke, Karel
    Kayaleh, Omar
    Lenz, Heinz-Josef
    Keaton, Mark
    Katz, Terry
    Ballal, Shaila
    Rowinsky, Eric K.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1597 - 1606
  • [30] A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H. Ko
    Hagop Youssoufian
    Jayne Gurtler
    Karel Dicke
    Omar Kayaleh
    Heinz-Josef Lenz
    Mark Keaton
    Terry Katz
    Shaila Ballal
    Eric K. Rowinsky
    Investigational New Drugs, 2012, 30 : 1597 - 1606
12345